Apple Inc. (AAPL)
Apple Stock Eyes Big Gains After Beat-and-Raise
Apple Inc (NASDAQ:AAPL) reported a top- and bottom-line beat for its fiscal first quarter after yesterday's close.
Friday Morning Movers: AAPL Earnings, Tariffs Imminent
Apple (AAPL) shsares are rising premarket to close the week after its earnings beat expectations and saw broad bullish analyst support. Alex Coffey breaks down the report, and discusses why markets are positive despite President Trump's imminent 25% tariffs for Canada and Mexico.
Analysts revise Apple stock price targets after earnings
Apple (NASDAQ: AAPL) has seen significant volatility since the beginning of the year. On December 26, 2024, Apple stock reached an all-time high (ATH) price of $259.02.
DeepSeek's Impact on the Mag 7 Stocks
Harvard Business School Professor Mihir Desai breaks down his theory on what this week's Nvidia route can tell us about the future of AI and the danger of placing too much market share in big tech. -------- More on Bloomberg Television and Markets Like this video?
Apple Q1 Earnings Beat Estimates, Services Drive Top-Line Growth
AAPL's first-quarter fiscal 2025 results benefit from strong services growth despite a decline in iPhone sales.
Apple is a low growth stock with a high multiple, says Dan Niles
Dan Niles, Niles investment Management founder and portfolio manager, joins 'Squawk Box' to discuss Apple's quarterly earnings results, impact of DeepSeek's AI development on Apple, and more.
Prescient Therapeutics prepares for transformative year with new CEO and key FDA clearance
With new CEO James McDonnell in place and FDA clearance for its Investigational New Drug application, 2025 could be a signpost year for Prescient Therapeutics as it continues to develop PTX-100. It was a big December quarter for the company after its IND application for the PTX-100 Phase 2 clinical trial in r/rCTCL was successfully cleared by the US Food and Drug Administration (FDA), allowing for the study's immediate initiation Significant progress was also made in the clinical development of CellPryme and re-engineering of OmniCAR, with growing collaboration interest from channel and R&D partners. The company had a cash and term deposit balance of $8.4 million at December 31, with an additional $3.7 million R&D Tax Incentive Rebate received on January 10. Prescient received clearance from the FDA for its IND application, allowing the Phase 2 clinical trial of PTX-100 to proceed. PTX-100 is a first-in-class inhibitor targeting the RAS-family pathway, with the trial focusing on relapsed and refractory cutaneous T-cell lymphomas (r/r CTCL). The IND clearance represents a key milestone for the company, enabling the formal initiation of the study. During the reporting period, Prescient dedicated significant resources to preparing the IND application, engaging clinical and industry experts to refine the study design, trial implementation strategy, and responses to FDA inquiries. The company is now moving forward with site selection, assessing clinical locations in Australia, the United States, and Europe, with up to 15 sites expected to be activated. Additionally, Prescient remains interested in exploring PTX-100's potential in Peripheral T-Cell Lymphoma (PTCL) and is evaluating strategies to generate further clinical data in this patient population. What is PTX-100? PTX-100 is a first-in-class compound designed to inhibit geranylgeranyl transferase-1 (GGT-1), a key enzyme involved in cancer growth. By blocking GGT-1, PTX-100 disrupts oncogenic Ras pathways, preventing the activation of Rho, Rac, and Ral signalling circuits in cancer cells, ultimately inducing apoptosis. It is believed to be the only GGT-1 inhibitor currently in clinical development. The compound has demonstrated safety and early clinical activity in a previous Phase 1 study and a recent pharmacokinetics/pharmacodynamics (PK/PD) basket study across hematological and solid malignancies. The United States Food and Drug Administration (FDA) has granted PTX-100 Orphan Drug Designation for all T-cell lymphomas and recently approved an Investigational New Drug (IND) application for a Phase 2 study focusing on cutaneous T-cell lymphomas. Prescient’s CellPryme platform continues to gain momentum in both preclinical and clinical development. During Q4 2024, the company presented data on cell therapy manufacturing and adjuvant enhancements at the CAR-TCR Summit in Boston and the American Society of Hematology conference in San Diego, generating increased interest in potential collaborations. Following these engagements, Prescient has initiated multiple partnerships involving CellPryme-M, working with potential collaborators to explore ways to enhance their cell therapy programs. The company intends to provide investors with updates on the progress of these partnerships as developments allow. Additionally, Prescient is in the early stages of evaluating first-in-human clinical trials for CellPryme-A. If initiated, these trials will investigate CellPryme-A’s potential in combination with CAR-T therapies. Meanwhile, significant progress has been made in OmniCAR development following extensive troubleshooting of technical challenges and the engineering of new, optimised molecular variants. With encouraging results achieved, Prescient will continue development efforts, with further validation work planned. What is CellPryme? CellPryme-M: Prescient’s CellPryme-M is a novel, clinic-ready technology designed to enhance adoptive cell therapy by shifting T cells towards a central memory phenotype. This improves persistence and increases the ability of cells to locate and penetrate tumours. The process is a non-disruptive, 24-hour step within cell manufacturing. Cell therapies requiring enhanced manufacturing productivity or increased in vivo potency and durability are well-suited for CellPryme-M. CellPryme-A: CellPryme-A is an adjuvant therapy administered alongside cellular immunotherapy to counteract the suppressive tumour microenvironment. It significantly reduces regulatory T cells, promotes CAR-T cell expansion in vivo, and enhances tumour penetration. These improvements result in better tumour cell killing and increased host survival. When used in combination with CellPryme-M pre-treated CAR-T cells, these benefits are further amplified. New CEO James McDonnell is a seasoned biopharmaceutical executive with over 25 years of experience in the global pharmaceutical industry, with a strong focus on blood disorders and haematological malignancies, including myeloma, myelodysplasia, and chronic myeloid leukaemia (CML). His strategic leadership has driven outstanding commercial success, underpinned by his ability to cultivate high-performing team cultures. Apple Inc (NASDAQ:AAPL, ETR:APC) reported quarterly earnings that topped Wall Street expectations on Thursday, with record revenue of $124.3 billion, despite a decline in iPhone sales in China. The company posted earnings per share (EPS) of $2.40, surpassing analysts' estimates of $2.35. Revenue rose 4% from the previous year, exceeding the $124.12 billion consensus forecast. However, iPhone sales dropped 11.1% in China during the key December quarter, highlighting concerns that Apple’s artificial intelligence push has yet to spark a new upgrade cycle for its flagship product. While the earnings beat provided some relief to investors, the report showed ongoing challenges in one of Apple's most critical markets. Apple shares were flat to slightly positive in after-hours trading.
Zino: Apple's exposure in China has dropped from 20% to 15%
Angelo Zino, Senior Equity Analyst at CFRA Research, raises his price target for Apple to $270, citing the company's resilience despite concerns over China and the lack of an AI offering there. He argues that Apple's strength lies in its services business and cost reductions, which the market underestimates.
Apple: The China Revenue Decline That No One Realizes Is Bullish
Apple's China revenues fell 11% YoY. But contrary to what you may think; it does not spell weak demand in that region. In fact, China demand is stronger than expected. Product and iPhone sales have been stagnant for the past 3 years. The iPhone 16 Series launch missed estimates in the holiday season. But with a huge and still-growing installed base of products, AAPL is enjoying steady and robust double-digit growth in service revenues at double the gross margins vs. the product business.
Peninsula Energy prepares for first yellowcake production in June Quarter for Lance Uranium Project
Peninsula Energy Ltd expects to begin regulatory inspections and commissioning of the central processing plant (CPP) at the Lance Uranium Project in Wyoming, US, in the June quarter of 2025. The company also expects to begin production of the first dry yellowcake in the same quarter, once elution, precipitation and filtration circuits are sequentially commissioned in advance. Peninsula has previously forecast commissioning at the end of the March quarter, but challenging weather conditions and supply chain issues necessitated the re-schedule to later in the year, which may also affect production guidance for the calendar year. PEN says its board has been frustrated with the delay, working closely with contractors Samuel Engineering, Inc and Samuel EPC, LLC to conclude the project as quickly as possible. The company has been loading uranium onto resin for elution since December last year and will be looking into short term options to store the resin until the commissioning of the CPP is completed. As part of his planned on-boarding, newly appointed managing director George Bauk will be on site in Wyoming from Monday February 3 for an extended period to oversee the ongoing commissioning and ramp-up phase. The board believes it is likely that 2025 calendar year production guidance will need to be revised downward from previous forecasts of 600,000 pounds of uranium. With a cash balance of US$44.9 million at the end of last year, the company is well equipped to negotiate with providers of additional funding to decrease liquidity risk during the important commissioning and ramp-up phase over the course of CY2025. Apple Inc (NASDAQ:AAPL, ETR:APC) reported quarterly earnings that topped Wall Street expectations on Thursday, with record revenue of $124.3 billion, despite a decline in iPhone sales in China. The company posted earnings per share (EPS) of $2.40, surpassing analysts' estimates of $2.35. Revenue rose 4% from the previous year, exceeding the $124.12 billion consensus forecast. However, iPhone sales dropped 11.1% in China during the key December quarter, highlighting concerns that Apple’s artificial intelligence push has yet to spark a new upgrade cycle for its flagship product. While the earnings beat provided some relief to investors, the report showed ongoing challenges in one of Apple's most critical markets. Apple shares were flat to slightly positive in after-hours trading.
Firebird Metals makes Chinese LMFP battery strategy progress in December 2024 quarter
During the last quarter of 2024 Firebird Metals Ltd was busy across its key projects, making progress on its Chinese LMFP battery strategy and forging partnerships to develop the Oakover manganese project in Western Australia. During the quarter, Firebird’s subsidiary, Hunan Firebird Battery Technology Co., Ltd. (HFBT), received preliminary design approval from the Jinshi High-Tech Industrial Park Committee for its proposed battery-grade high-purity manganese sulphate plant in Jinshi, Hunan, China. In less than 12 months since its incorporation, HFBT has secured all critical permits and remains on schedule and within budget. In a key technological breakthrough, Firebird’s pilot calcining kiln demonstrated energy savings of up to 70% compared to conventional kilns, reducing energy consumption to 80-100 kWh per tonne of feed. This equates to a cost reduction of US$30 per tonne, or 5% of total production costs. Firebird entered into a strategic collaboration agreement with Central South University to develop a processing method for Lithium Manganese Iron Phosphate (LMFP) as a cathode active material (CAM). This further strengthens its LMFP strategy. Early-stage test work is set to begin at Firebird’s R&D centre in Jinshi, with initial results expected in Q1 2025. Firebird signed an agreement with the Karlka Nyiyaparli Aboriginal Corporation (KNAC) concerning Mining Lease 52/1086. This agreement covers key commercial considerations, including financial benefits upon production, as well as cultural heritage protection and environmental management. Oakover remains central to Firebird’s long-term strategy, providing ore for its battery-grade manganese sulphate plants. Key workstreams for the next 12 months will focus on environmental studies and securing necessary regulatory approvals. Firebird completed the farm-out of an 80% interest in its Direct Shipping Ore (DSO) Manganese Assets in Western Australia’s East Pilbara region to Macro Metals Limited (ASX: M4M). The agreement includes minimum expenditure commitments and drilling requirements, allowing Firebird to focus on its core manganese projects. As of December 31, 2024, Firebird held a cash position of A$3.1 million. The company also received A$889,546 through the Australian Government’s R&D Tax Incentive program, bolstering its financial reserves. Apple Inc (NASDAQ:AAPL, ETR:APC) reported quarterly earnings that topped Wall Street expectations on Thursday, with record revenue of $124.3 billion, despite a decline in iPhone sales in China. The company posted earnings per share (EPS) of $2.40, surpassing analysts' estimates of $2.35. Revenue rose 4% from the previous year, exceeding the $124.12 billion consensus forecast. However, iPhone sales dropped 11.1% in China during the key December quarter, highlighting concerns that Apple’s artificial intelligence push has yet to spark a new upgrade cycle for its flagship product. While the earnings beat provided some relief to investors, the report showed ongoing challenges in one of Apple's most critical markets. Apple shares were flat to slightly positive in after-hours trading.
